A way forward for Alzheimer’s disease drug development

Written by George Perry (University of Texas at San Antonio, TX, USA)

George Perry (University of Texas at San Antonio, TX, USA) is a Professor of Biology and Chemistry and is the Editor-in-Chief of the Journal of Alzheimer’s Disease. He has been working in the field of Alzheimer’s since the early 1980s. In this interview, we had the pleasure of speaking with George to discuss his opinions on the recent trial results from ENGAGE, EMERGE and DIAN-TU. For example, what can we take from these findings? Are the underlying issues with anti-amyloid therapies related to dose? Could early in the disease course still not be early enough? Considering the trial results so...

To view the full article, please register now for access

It's completely free